Anemia Analysis in Intermediate or High-Risk MF Patients | Jakafi®/Jakafi XR™ (ruxolitinib) Skip to main content
Treatment decisions displayed among circulating red blood cells Efficacy_OS_Anemia-mobile

For adults with intermediate- or high-risk MF

Intervene with JAKAFI XR™ (ruxolitinib) at diagnosis, regardless of anemia

The COMFORT-I trial included patients who were experiencing anemia1*

46%

of patients receiving JAKAFI® (ruxolitinib) had anemia at baseline.† Mean Hb was 9.2 g/dL (range, 6.6 g/dL to 13.7 g/dL)1

New-onset anemia observed in the COMFORT-I trial2,3

JAKAFI (n=155)Placebo (n=151)
All Grades, %Grades 3 and 4, %All Grades, %Grades 3 and 4, %
96458719

Identification and management of new-onset anemia2

  • Perform a pretreatment CBC, and monitor CBCs every 2 to 4 weeks until doses are stabilized and then as clinically indicated
  • Dose modifications and/or blood transfusions may be required for patients who develop anemia

<1%

of patients receiving JAKAFI in the COMFORT-I study discontinued due to anemia2

  • *COMFORT-I was a randomized, double-blind, placebo-controlled phase 3 study with 309 patients with intermediate-2–risk or high-risk MF. The primary endpoint was the proportion of patients achieving a ≥35% reduction in spleen volume from baseline to week 24 as measured by CT or MRI.2,3
  • †Anemia at baseline was defined as RBC transfusion within the first 12 weeks prior to the initial dose of JAKAFI, or baseline Hb <10 g/dL.1

COMFORT-I additional analysis

Spleen volume reduction data in patients with anemia1,3

Effect of New-Onset Grade 3/4 Anemia on Spleen Volume Over Time1,3

Limitations: This analysis is exploratory in nature and these results should be interpreted with caution

Effect of New-Onset Grade ¾ Anemia on Spleen Volume Graph

COMFORT trials post hoc pooled analysis

Spleen volume reduction with JAKAFI across a range of Hb levels at 3 years1

Post Hoc Exploratory Pooled Analysis of SVR ≥35% Rate in the COMFORT Trials1,a

Limitations: This analysis is exploratory in nature and these results should be interpreted with caution

Comparison of SVR outcomes across Hb levels

COMFORT-I additional analysis

Effect of new-onset anemia on total symptom score1,3

Effect of New-Onset Grade 3/4 Anemia on TSS Over Time1,3

Limitations: This analysis is exploratory in nature and these results should be interpreted with caution

TSS changes over time by anemia status and treatment

Hb partially recovered to a new steady state after initial decrease and remained stable over time4

  • Mean decreases in Hb levels reached a nadir of approximately 1.5 g/dL to 2 g/dL below baseline after 8 to 12 weeks of therapy and then gradually recovered to reach a new steady state that was approximately 1 g/dL below baseline4
  • Limitations: This analysis is exploratory in nature and these results should be interpreted with caution

Mean Hb Levels Over Time4

Mean hemoglobin levels over time with Jakafi

By week 36, the proportion of patients on JAKAFI requiring RBC transfusions‡ decreased to levels similar to placebo and remained stable over time5

  • During randomized treatment, 41% of patients treated with JAKAFI and 47% of patients treated with placebo became newly transfusion independent3
  • Through week 24, 60% of patients treated with JAKAFI and 38% of patients receiving placebo required RBC transfusions2
  • 123 of 155 patients receiving JAKAFI were transfusion independent at baseline, compared with 119 of 151 receiving placebo. Of the 123 transfusion-independent patients receiving JAKAFI, 27% became transfusion dependent§ during the 8 weeks before data cutoff, compared with 14% receiving placebo1

Proportion of Patients Requiring RBC Transfusions During the Previous 4 Weeks5

Graph of RBC transfusion rates during treatment
  • ‡One or more units of RBCs.5
  • §New-onset transfusion dependence was defined as the use of ≥2 units of RBC product(s) during the final 8 weeks before data cutoff in a patient who was not transfusion dependent at baseline.3

BAT=best available therapy; CBC=complete blood count; COMFORT=COntrolled MyeloFibrosis study with ORal JAK inhibitor Treatment; CT=computed tomography; Hb=hemoglobin; JAK=Janus kinase; MF=myelofibrosis; MPN=myeloproliferative neoplasm; MRI=magnetic resonance imaging; OS=overall survival; RBC=red blood cell; SEM=standard error of the mean; SVR=spleen volume reduction; TSS=Total Symptom Score.

References: 1. Data on file. Incyte Corporation. Wilmington, DE. 2. JAKAFI/JAKAFI XR Prescribing Information. Wilmington, DE: Incyte Corporation. 3. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807. Supplementary appendix available at: https://www.nejm.org/doi/full/10.1056/nejmoa1110557. 4. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4):479-488. 5. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98(12):1865-1871. Supplementary appendix available at: https://haematologica.org/article/view/6861.

 
 

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Thrombocytopenia, Anemia and Neutropenia

  • JAKAFI®/JAKAFI XR™ (ruxolitinib) can cause dose‑related effects of thrombocytopenia, anemia and neutropenia. Perform a pre‑treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated.
  • Manage thrombocytopenia by reducing the dose or temporarily interrupting JAKAFI/JAKAFI XR. Platelet transfusions may be necessary.
  • Patients developing anemia may require blood transfusions and/or dose modifications of JAKAFI/JAKAFI XR.
  • Severe neutropenia (ANC <0.5 × 109/L) was generally reversible by withholding JAKAFI/JAKAFI XR until recovery.

INDICATIONS AND USAGE

JAKAFI®/JAKAFI XR™ (ruxolitinib) is for treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.

JAKAFI/JAKAFI XR is for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.

JAKAFI/JAKAFI XR is for treatment of steroid‑refractory acute graft‑versus‑host disease (aGVHD) in adult and pediatric patients 12 years and older.

JAKAFI/JAKAFI XR is for treatment of chronic graft‑versus‑host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

Risk of Infection

  • Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting JAKAFI/JAKAFI XR until active serious infections have resolved. Observe patients receiving JAKAFI/JAKAFI XR for signs and symptoms of infection and manage promptly.

Tuberculosis

  • Tuberculosis (TB) infection with JAKAFI/JAKAFI XR has been reported. Observe patients taking JAKAFI/JAKAFI XR for signs and symptoms of active TB and manage promptly. Prior to initiating, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting in patients with evidence of active or latent TB. Continuation during treatment of active TB should be based on the overall risk‑benefit determination.

Progressive Multifocal Leukoencephalopathy

  • Progressive multifocal leukoencephalopathy (PML) has occurred with JAKAFI/JAKAFI XR treatment. If PML is suspected, stop JAKAFI/JAKAFI XR and evaluate.

Herpes Zoster and Herpes Simplex

  • Herpes zoster infection, reactivation and/or dissemination has been reported in patients receiving JAKAFI/JAKAFI XR. Advise patients about early signs and symptoms of herpes zoster and seek treatment. Monitor patients for the development of herpes simplex infections. If a patient develops evidence of dissemination of herpes simplex, consider interrupting treatment.

Hepatitis B

  • Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections.

Symptom Exacerbation Following Interruption or Discontinuation of Treatment

  • When discontinuing JAK‑Inhibitors, including JAKAFI/JAKAFI XR, myeloproliferative neoplasm‑related signs and symptoms may flare. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, disseminated intravascular coagulation (DIC), or multi‑organ failure. If any of these occur after discontinuation or while tapering JAKAFI/JAKAFI XR, evaluate and treat any intercurrent illness and consider restarting or increasing the dose. Instruct patients not to interrupt or discontinue JAKAFI/JAKAFI XR without consulting their physician. When discontinuing or interrupting JAKAFI/JAKAFI XR for reasons other than life‑threatening toxicities, consider gradual tapering rather than abrupt discontinuation.

Non‑Melanoma Skin Cancer (NMSC)

  • NMSC including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations.

Lipid Elevations

  • Treatment with JAKAFI/JAKAFI XR has been associated with increases in total cholesterol, low‑density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8‑12 weeks after initiation.

Major Adverse Cardiovascular Events (MACE)

  • Another JAK‑inhibitor has increased the risk of major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers), in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur.

Thrombosis

  • Another JAK‑inhibitor has increased the risk of thrombosis, including deep venous thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis (compared to those treated with TNF blockers), in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. In patients with myelofibrosis (MF) and polycythemia vera (PV), the rates of thromboembolic events were similar in JAKAFI/JAKAFI XR and control treated patients. Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately.

Secondary Malignancies

  • Another JAK‑inhibitor has increased the risk of lymphoma and other malignancies, excluding NMSC (compared to those treated with TNF blockers), in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. Patients who are current or past smokers are at additional increased risk.

Adverse Reactions

  • In myelofibrosis, the most common hematologic adverse reactions (incidence >20%) were thrombocytopenia and anemia. The most common nonhematologic adverse reactions (incidence ≥15%) were bruising, dizziness and headache.
  • In polycythemia vera, the most common hematologic adverse reactions (incidence >20%) were anemia and thrombocytopenia. The most common nonhematologic adverse reactions (incidence ≥15%) were diarrhea and dizziness.
  • In acute graft‑versus‑host disease, the most common hematologic adverse reactions (incidence >50%) were anemia, thrombocytopenia and neutropenia. The most common nonhematologic adverse reactions (incidence >50%) were infections (pathogen not specified) and edema.
  • In chronic graft‑versus‑host disease, the most common hematologic adverse reactions (incidence >35%) were anemia and thrombocytopenia. The most common nonhematologic adverse reactions (incidence ≥20%) were infections (pathogen not specified) and viral infections.

Drug Interactions

  • Avoid concomitant use with fluconazole doses greater than 200 mg. Dose modifications may be required when administering fluconazole doses of 200 mg or less, or with strong CYP3A4 inhibitors, or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy.

Pregnancy

  • Use during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking JAKAFI/JAKAFI XR should not breastfeed during treatment and for 2 weeks after the final dose.

Please see Full Prescribing Information for JAKAFI/JAKAFI XR.